A Worked Example: How to Requalify a New Antibody Lot for Western Blot

A practical old-versus-new lot comparison that moves from experimental setup to a documented pass, conditional pass, or fail decision.

Estimated reading time: 10–11 minutes

In This Article

1. A Lot Change Halfway Through a Study
2. Define What Must Remain Stable
3. Choose Samples That Can Reveal a Real Difference
4. Compare the Lots Without Changing the Rest of the Assay
5. Start at the Current Condition, Then Let the Data Decide Whether to Titrate
6. Read the Blot as a System, Not as a Single Band
7. Set the Decision Rules Before Looking at Lot B
8. Worked Results: Stronger Signal, Same Interpretation
9. Record the Decision and Put It Into Routine Use
10. Common Errors That Make Lot Comparisons Hard to Interpret
11. Conclusion

A Lot Change Halfway Through a Study

An antibody lot change can look harmless on paper. The catalog number, clone, host species, and recommended dilution may all stay the same. On the membrane, however, the replacement lot may produce a stronger target band, more haze, a new off-target band, or a weaker signal in low-expression samples.

Those differences matter most when the new data will be compared with results generated earlier in the study. A technical shift introduced by the antibody lot can be mistaken for a biological effect, particularly in longitudinal or semi-quantitative work.

This article follows one illustrative Western blot case from setup through approval. It assumes that the laboratory already understands the broader risk-based principles of lot requalification. For that cross-application framework, see the complete antibody lot-to-lot bridging guide.

1. Define What Must Remain Stable

The assay is semi-quantitative, so seeing a band is not enough. Lot B must preserve the features that support the study's interpretation.

• A target band at the expected molecular weight.
• Reliable detection of high-, intermediate-, and low-expression samples.
• No target-sized band in a knockout or confirmed negative lysate.
• Background low enough for reproducible densitometry.
• No new nonspecific band that interferes with the target region.
• The same relative sample order: high > intermediate > low.
• No change in the direction of the biological comparison.

This is the first point at which the case becomes specific to Western blot. The question is not whether the two images look identical; it is whether Lot B preserves the information the blot is being used to measure.

2. Choose Samples That Can Reveal a Real Difference

A single strong positive lysate is a weak challenge for a replacement lot. Even an antibody with reduced sensitivity may still produce a dark band when the target is abundant. The comparison should include samples that test both sensitivity and specificity.

The controls do different jobs. A knockout lysate tests target dependence; a no-primary control tests the detection system; a loading control or total-protein stain supports normalization. For a broader review, see Boster Bio's Western blot control design guide.

3. Compare the Lots Without Changing the Rest of the Assay

The cleanest lot comparison changes one variable: the primary-antibody lot. Sample preparation, electrophoresis, transfer, blocking, detection, imaging, and analysis should remain matched.

• Prepare all lysates using the same extraction and quantification workflow.
• Load the same protein amount and use the same gel percentage and running conditions.
• Transfer with the same membrane type, buffer, time, and instrument settings.
• Use the same blocking reagent, secondary-antibody lot, wash schedule, and ECL substrate.
• Acquire both blots with the same instrument and unsaturated exposure settings.
• Apply the same background subtraction and densitometry method.

If sample preparation has not already been standardized, review the Western blot sample preparation guide. Laboratories building the workflow for the first time can also use the complete Western blot protocol as the procedural reference.

Same Membrane or Parallel Membranes?

Using one membrane can reduce run-to-run variation, but exposing different lanes to different primary-antibody lots is not always practical. Depending on the target and available equipment, the laboratory may use duplicate gels transferred in parallel, duplicate sample sets on a membrane that can be divided into equivalent sections, or a multichannel incubation device.

For this case, the laboratory runs matched duplicate gels and processes both membranes together. This is more realistic than claiming a same-membrane comparison when the incubation setup cannot physically isolate the two lots.

Match Working Concentration When Possible

The same dilution factor does not always mean the same amount of antibody. If Lot A is supplied at 1 mg/mL and Lot B at 0.5 mg/mL, testing both at 1:1,000 places Lot B at half the working concentration. When reliable stock concentrations are available, compare matched concentrations. When they are not, begin with the qualified dilution and record the limitation.

4. Start at the Current Condition, Then Let the Data Decide Whether to Titrate

The first run asks a practical question: can Lot B enter the existing method without a protocol change? Both lots are initially tested at the current qualified condition, with all other variables held constant.

A limited parallel titration is added only if the first comparison shows a meaningful signal or background shift, changes low-expression detection, introduces new bands, or suggests that one condition is close to saturation.

Both lots should be titrated in parallel. Optimizing only the replacement lot creates an unequal comparison. For a more detailed discussion of usable concentration windows, see How to Optimize Primary Antibody Dilution for Western Blot.

5. Read the Blot as a System, Not as a Single Band

Lot B should be evaluated across several linked measurements. A darker band is not automatically better if background rises at the same time, and a small numerical difference may be acceptable when specificity and sample ranking are unchanged.

Target Band and Normalized Signal

Confirm the expected band position, then measure background-corrected intensity using a predefined normalization method. Total-protein normalization, a validated loading-control protein, or a stable internal reference sample may be appropriate, depending on the assay.

Do not assume that GAPDH, beta-actin, or another housekeeping protein remains stable under every treatment. When a housekeeping protein is used, select it with the target molecular weight, sample type, treatment, and cellular compartment in mind. Boster Bio's loading control antibody hub provides an experiment-focused selection workflow.

Background and Nonspecific Bands

Measure background consistently near the target region or across the relevant lane area. Record any new bands, their approximate molecular weights, and whether they interfere with target identification. A faint band far from the target may not affect the assay; a new band close to 65 kDa may be unacceptable even if it is not intense.

Low-Expression Detection and Sample Ranking

The low-expression sample reveals whether sensitivity has moved close to the practical detection limit. For this semi-quantitative assay, the relative order of samples also matters. A uniform 15% increase across all samples may leave the biological pattern intact. A change from high > intermediate > low to high > low > intermediate would be more serious, even if every lane still contains a visible band.

6. Set the Decision Rules Before Looking at Lot B

The laboratory defines the decision criteria before reviewing the replacement-lot result. The criteria are tied to the assay's intended use and historical variation rather than to a universal percentage cutoff.

If the laboratory lacks enough historical data to justify a numerical equivalence range, the study should not pretend otherwise. The bridge may support a qualitative or semi-quantitative decision, but not a strong claim of quantitative equivalence.

7. Worked Results: Stronger Signal, Same Interpretation

The first matched run produces the following illustrative results. These numbers demonstrate the decision process; they are not universal acceptance limits.

Lot B is consistently stronger, but it does not change the parts of the blot that matter. The knockout remains negative, the low-expression sample remains detectable, no interfering band appears, and the sample ranking is unchanged.

Because the signal has shifted upward, the laboratory runs a limited parallel titration. A slightly higher dilution brings Lot B into the established working range without increasing background or reducing low-expression detection. The revised condition is confirmed in a second run.

The Decision: Conditional Pass

This is not a failure disguised as optimization. The adjustment is limited, documented, and confirmed. It does not change the biological interpretation or require a broader redesign of the assay.

What Would Have Caused a Fail?

• A target-sized band appeared in the knockout lysate.
• The low-expression sample was no longer reproducibly detected.
• A new band interfered with the expected target region.
• Background prevented reliable densitometry.
• Sample ranking or the direction of group differences changed.
• A limited titration could not recover acceptable performance.

Before rejecting the lot, rule out transfer, blocking, washing, secondary-antibody, imaging, and sample-handling problems. Boster Bio's Western blot troubleshooting guide can help separate a true lot effect from a workflow problem.

8. Record the Decision and Put It Into Routine Use

The bridge is not complete until another scientist can reconstruct what was compared and why the lot was approved.

• Antibody target, catalog number, and old and new lot numbers.
• Stock concentrations, working concentrations or dilutions, and storage history.
• Sample identities, protein load, gel, transfer, blocking, and incubation conditions.
• Secondary-antibody lot, detection substrate, instrument, and exposure settings.
• Raw unedited images, densitometry method, and normalization approach.
• Predefined criteria, quantitative comparison, final decision, reviewer, and date.
• The approved revised dilution and any restrictions on use.

For the first few routine runs with Lot B, the laboratory continues to include the banked internal reference lysate. This provides an early check that the new working condition remains stable outside the bridging experiment.

Common Errors That Make Lot Comparisons Hard to Interpret

Conclusion

A useful Western blot lot bridge evaluates more than whether the expected band is still visible. It asks whether the new lot preserves target-dependent specificity, usable sensitivity, manageable background, sample ranking, and the biological interpretation required by the study.

Begin while enough of the qualified lot remains. Compare both lots in a matched run, include samples that challenge sensitivity as well as specificity, and decide against criteria set before the data are reviewed.

A stronger or weaker signal does not automatically mean the new lot has failed. In this example, a small and documented dilution adjustment supported conditional approval because the assay's scientific meaning did not change.

For additional Western blot protocols, optimization articles, and troubleshooting resources, visit the Western Blotting Technical Resource Center. Researchers evaluating a Boster antibody for a new sample type or application can also review the Free Antibody Validation program for eligible antibodies.